40: Outcomes of a Prospective Trial of NMDP-Facilitated Unrelated Donor (UD) PBSC Hematopoietic Cell Transplantation (HCT) for Leukemia and Myelodysplasia: Comparable Survival Regardless of Regimen Intensity and Improved Survival with Higher Cell Doses  by Pulsipher, M.A. et al.
Oral Presentations 17a significant proportion of patients with high-risk hematological
disease. This is the first report containing data on long-term toxicity
and disease control after any strategy of donor graft manipulation to
selectively reduce HLA-mismatched alloreactivity.
39
FEASIBILITY OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN CONGENITAL CHILDHOOD DISEASES
Martinez, C.1, Tolar, J.1, Wagner, J.E.1, Tan, P.-L.1, DeFor, T.1,2,
Baker, K.S.1, Orchard, P.J.1. 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN.
An HLA-matched sibling donor has been the initial choice for
children requiring allogeneic hematopoietic cell transplant
(HCT). However, less than 30%HCT patients have a matched re-
lated donor (MRD). In the past decade, umbilical cord blood (UCB)
transplantation has emerged as an attractive alternative for patients
without a MRD. Recent studies have shown the advantages of using
UCB over bone marrow as an alternative graft source for children
with acute leukemias. However, there is less information available
regarding the utilization of unrelated UCB transplantation for chil-
dren with non-malignant diseases. We report the use of an unre-
lated UCB myeloablative transplantation in fifty-five consecutive
children with a median age of 2.6 years (range, 0.2–40.6 years)
with Wiskott-Aldrich syndrome, Chediak-Higashi syndrome, he-
mophagocytic lymphohistiocytosis, langerhans cell histiocytosis,
osteopetrosis, Diamond-Blackfan anemia, Hurler syndrome,Maro-
teaux-Lamy, a-mannosidosis, cerebral X-linked adrenoleuko-
dystrophy, metachromatic leukodystrophy and globoid-cell
leukodystrophy transplanted over 11.5 year period (1994–2006).
Patients received grafts matched at 6 (14%), at 5 (56%), or at 4
HLA alleles (30%). The median total nucleated cell dose and the
median CD341 cell dose were 5.4  107/kg and 4.2  105/kg, re-
spectively. The median time to neutrophil recovery was 20 days
(range, 10–45 days) and the incidence of neutrophil recovery by
day 42 was 86%. The incidence of platelet recovery by 6 months
was 73%. In the group of immune or hematological disorders, 6
of 10 patients achieved complete donor chimerism by day 21. In
the metabolic disorders group, 8 of 13 patients achieved a complete
donor chimerism at a median of 21 days and 3 additional patients at
a median day of 95 days. In the leukodystrophy group, 6 of 12 pa-
tients achieved completed donor chimerism by day 21 and 4 patients
achieved complete donor chimerism at a median of 120.5 days. The
incidences of grade II-IV and grade III-IV acute GvHD were 34%
and 12%, respectively. Chronic GvHD was observed in only 5% of
cases. The overall survival was 62% at 2-years. These results dem-
onstrate the usefulness of unrelated UCB as an alternate stem cell
source for patients lacking an HLA matched related or unrelated
donor. The use of unrelated UCB transplantation creates new op-
portunities in the treatment of non-malignant diseases requiring ex-
pedient HCT in order to prevent irreversible disease progression.
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OUTCOMES OF A PROSPECTIVE TRIAL OF NMDP-FACILITATED UNRE-
LATED DONOR (UD) PBSC HEMATOPOIETIC CELL TRANSPLANTATION
(HCT) FOR LEUKEMIA ANDMYELODYSPLASIA: COMPARABLE SURVIVAL
REGARDLESS OF REGIMEN INTENSITY AND IMPROVED SURVIVALWITH
HIGHER CELL DOSES
Pulsipher, M.A.1, Chitphakdithai, P.2, Logan, B.3, Leitman, S.4,
Anderlini, P.5, Klein, J.3, Horowitz, M.3, Miller, J.2, King, R.2,
Confer, D.2. 1University of Utah, Salt Lake City, UT; 2Nat Marrow
Donor Prog, Minneapolis, MN; 3Center for International Blood and
Marrow Transplant Research, Milwaukee, WI; 4NIH, Bethesda, MD;
5MD Anderson Cancer Center, Houston, TX.
We report outcomes of 932 recipients (rcpts) of UD PBSCHCT
facilitated by NMDP from 1999 through 2003 (median f/u 3.3 yrs).
Indications were AML (419 rcpts), ALL (185 rcpts), CML (134
rcpts), and MDS (194 rcpts). Preparative regimens included mye-
loablative (MA, N 5 611), reduced intensity (RI, N 5 160), and
non-myeloablative (NMA, N5 161). Distributions of HLA-match
grade, CMV status, Karnofsky scores (KS), and donor characteris-
tics were similar between the preparative regimens, however, fewer
rcpts with advanced disease received NMA (p5 0.035), while morercpts with coexisting diseases received RI and NMA regimens (p\
0.001). The age of rcpts receiving RI and NMA regimens was sub-
stantially higher than rcpts receiving MA regimens (median RI 56
yo, NMA 57 yo, MA 38 yo, p\0.001). Optimal cell dose cutpoints
for TNC,MNCandCD341were determined based onMartingale
residuals from Cox regression analyses. For MA rcpts, CD341
counts .3.8  106/kg improved day 125 neutrophil and day 160
platelet engraftment; higher infused TNC doses (.6.9  108/kg)
predicted decreased grade III-IV aGVHD, while improved overall
survival (OS) and reduced TRM (RR 0.55) were seen with MNC
doses .4.4  108/kg. For RI and NMA rcpts, OS was higher and
TRM was decreased in those receiving .3.8  106 CD341cells/
kg. Of note, cGVHD was not increased with higher cell doses in
rcpts of any type of preparative regimen. Additional predictors of
improved OS included early disease, and for MA rcpts only,
HLA-matched donors, KS $ 90, and CsA-based GVHD prophy-
laxis. Three year OS and DFS of rcpts receiving MA, RI, and
NMA approaches were similar (33, 35, and 32% OS; 33, 30, and
29% DFS: MA, RI, and NMA, respectively). Higher risk of relapse
at 3 yrs in RI and NMA approaches (35, 37 vs. 24% RI, NMA, MA,
respectively, p\ 0.001) was offset by higher 3 yr TRM using MA
regimens (43 vs. 34, 34% MA, RI, NMA, respectively, p 5 0.008).
Sub-analyses of 1) rcpts with AML-CR1, 2) rcpts with AML/
MDS/CML (excluding ALL), or 3) rcpts between the ages of 40–
60 with AML/MDS also showed similar survival with MA vs. RI
vs. NMA approaches. In summary, rcpts of UDPBSCHCT receiv-
ing preparative regimens differing in intensity experienced similar
survival. Higher cell doses resulted in more rapid engraftment,
less severe aGVHD (MA rcpts), and better 3 year OS (37 vs. 18%,
MA; 36 vs. 21% RI/NMA, p\ 0.001), but did not increase the
risk of cGVHD.IMMUNE RECONSTITUTION41
PRE-TRANSPLANT ADMINISTRATION OF KERATINOCYTE GROWTH FAC-
TOR AFFECTS PERIPHERAL T-CELL HOMEOSTASIS THROUGH IN-
CREASED RECENT THYMIC EMIGRANT EXPORT AND AFFECTS THE
COURSE OF MURINE CHRONIC GRAFT-VS.-HOST DISEASE
Chu, Y.-W., Bodnar, D., Singh, N., Gress, R. National Cancer Institute,
Bethesda, MD.
Accelerated recovery of thymic function following allogeneic he-
matopoietic stem cell transplantation (allo-HSCT) not only pro-
vides a sufficiently broad repertoire of T-cell responses to
pathogens, but also is thought to play a role in affecting the outcome
of graft-vs.-host disease (GVHD) through the restoration of central
tolerance and/or the production of regulatory cell populations that
may blunt the effect of donor-derived alloreactive T-cell popula-
tions. Keratinocyte growth factor (KGF) has been shown in murine
models to accelerate thymic function and ameliorate acute GVHD,
but it is unclear whether the latter involves a thymic-dependent
mechanism of increased T-cell production and/or cytoprotection
of epithelial cells in target organs of GVHD. We examined the ef-
fect of pre-transplant administration of KGF in the B10.D2 into
BALB/c murine model of chronic GVHD (cGVHD). KGF treated
mice had significantly increased thymic function as assessed by enu-
meration of thymocyte populations, analysis of thymic cytoarchi-
tecture, and enumeration of peripheral T-cell subsets and recent
thymic emigrants (RTE). Significantly, enhanced export of RTE
by KGF decreased peripheral T-cell homeostatic expansion and
downregulated expression of activation markers, suggesting that
RTE effectively compete with post-thymic T-cells for limited cyto-
kines and contact-dependent niches post-allo-HSCT. Parallel ex-
periments in thymectomized recipients receiving KGF exhibited
no changes in cell cycle profiles or activation profiles of peripheral
T-cells. Pre-transplant KGF administration improved clinical
cGVHD outcomes in both thymus-intact and thymectomized re-
cipients. However, there were no observable differences in the
course of cGVHDbetweenKGF treated thymus intact and thymec-
tomized mice, suggesting that enhanced thymic function by KGF
did not provide for any additional benefit to the cytoprotective ef-
fects of KGF. One contributing factor for this observation was
